Clinical Trials Logo

Glomerulonephritis, Membranous clinical trials

View clinical trials related to Glomerulonephritis, Membranous.

Filter by:

NCT ID: NCT05667896 Not yet recruiting - Clinical trials for Idiopathic Membranous Nephropathy

Prognostic Model of GC/TAC in the Treatment of MN

Start date: June 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of glucocorticoid + tacrolimus. The main questions it aims to answer are: - to explore the factors that can predict the prognosis difference in patients with IMN under the treatment of glucocorticoid + tacrolimus - to establish a clinical prediction model and verify it to provide a reference for the early Participants will receive standard the treatment of glucocorticoid + tacrolimus treatment and will then be divided into remission and non remission groups based on the treatment effect after the standard treatment cycle. Blood, urine, and fecal samples were collected from patients to explore possible factors influencing treatment efficacy. Researchers will compare [remission group and non-remission group] to see if the gut microbiota and its metabolites are factors that influence the efficacy of treatment.

NCT ID: NCT05667883 Not yet recruiting - Clinical trials for Idiopathic Membranous Nephropathy

Prognostic Model of GC/CTX in the Treatment of MN

Start date: June 2023
Phase:
Study type: Observational

The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of glucocorticoid + cytoxan. The main questions it aims to answer are: - to explore the factors that can predict the prognosis difference in patients with IMN under the treatment of glucocorticoid + cytoxan - to establish a clinical prediction model and verify it to provide a reference for the early Participants will receive standard glucocorticoid + cytoxan treatment and will then be divided into remission and non remission groups based on the treatment effect after the standard treatment cycle. Blood, urine, and fecal samples were collected from patients to explore possible factors influencing treatment efficacy. Researchers will compare [remission group and non-remission group] to see if the gut microbiota and its metabolites are factors that influence the efficacy of treatment.

NCT ID: NCT05656963 Active, not recruiting - Thromboembolism Clinical Trials

The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD

Start date: September 1, 2021
Phase:
Study type: Observational

Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease

NCT ID: NCT05532111 Not yet recruiting - Efficacy and Safety Clinical Trials

Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

1. Main purpose: To evaluate the efficacy and safety of rituximab combined with tacrolimus in the treatment of intermediate and high-risk primary membranous nephropathy 2. Secondary research purposes: To describe the survival of patients with intermediate and high-risk primary membranous nephropathy treated with rituximab combined with tacrolimus; To describe renal survival in patients with intermediate and high-risk primary membranous nephropathy treated with rituximab combined with tacrolimus; 3. Exploratory research purposes: Feasibility of glucocorticoids-free therapy (rituximab combined with tacrolimus) in the treatment of intermediate and high-risk primary membranous nephropathy

NCT ID: NCT05514015 Recruiting - Clinical trials for Primary Membranous Nephropathy

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

Start date: March 29, 2024
Phase: Phase 4
Study type: Interventional

This was a prospective, randomized, multicenter clinical trial. Seventy-eight patients with primary membranous nephropathy (PMN) were randomly divided into intervention or control group. Intervention group was given rituximab combined with corticosteroids in induction therapy and the control group was given rituximab monotherapy. After 6 months, patients who had decreased 24h urinary protein by > 25% but did not achieve CR were given rituximab maintenance therapy. The complete response rate at 12 months was measured.

NCT ID: NCT05505500 Recruiting - Fluid Overload Clinical Trials

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

Prepare-NS
Start date: April 18, 2022
Phase:
Study type: Observational

Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome. Interviews with patients (child and adult) and parents of young children will be conducted. The information collected from the interviews will be used to develop a survey to use when testing new medications for Nephrotic Syndrome. Please consider participating in a 1-hour long interview with the Prepare-NS research study to discuss children and adults experiences with swelling.

NCT ID: NCT05428605 Recruiting - Clinical trials for Extramembranous Glomerulopathy

In Vitro Immunomodulation in Membranous Nephropathy Relapses

BIOGEM
Start date: May 23, 2022
Phase: N/A
Study type: Interventional

In order to propose the best therapeutic option to relapsed MN patients with strong activation of the Th17 pathway, the investigators propose to study in vitro the effect of different immunomodulators on the Th17/Treg balance, assessed by cytokine profile and lymphocyte phenotyping using flow cytometry.

NCT ID: NCT05398653 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Clinical Study of MIL62 in Primary Membranous Nephropathy

Start date: February 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study was divided into two stages. In the first stage (Phase Ib), 30 subjects were randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group. Tolerance to MIL62 was evaluated within 4 weeks after the first administration. If the overall safety is determined by the investigator and sponsor to be tolerable to MIL62, phase II enrollment will be initiated. The second stage was also randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups according to the ratio of 1:1:1, 30 subjects in each group, to evaluate the efficacy of MIL62 and cyclosporine in the treatment of primary membranous nephropathy. Eligible subjects in both phases received treatment and follow-up for a total of 104 weeks. The 76-week overall response rate was the primary endpoint.

NCT ID: NCT05162066 Terminated - Clinical trials for Membranous Nephropathy

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

RENEW
Start date: February 18, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

NCT ID: NCT05136456 Active, not recruiting - Clinical trials for Primary Membranous Nephropathy

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

Start date: December 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.